pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ABBVIE · news · pharmadog
← back to ABBVIE
News mentioning ABBVIE
148
stories
10d
RNAi drug specialist ADARx raises $446M IPO
biopharma dive
11d
Growth mode: 3 biotechs that are staffing up after series B raises
biospace
12d
Pharmas face off for manufacturing talent amidst reshoring efforts
biospace
13d
2026 IPO blitz continues with 4 new biotech filings
biospace
13d
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
biopharma dive
13d
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
fiercebiotech
14d
Iambic signs AbbVie deal, releases next generation of Enchant model
endpoints
17d
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
17d
BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data
fiercebiotech
18d
North Immunology joins biotech reverse merger boom with Aethlon deal
biopharma dive
18d
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
18d
Trending: Top biopharma disciplines with jobs live now
biospace
18d
Biopharma hiring hotspots: States, disciplines where demand is highest
biospace
19d
Deep dive: Psychedelics back on FDA’s doorstep
biospace
19d
Novartis ends ALS program after phase 2 flop, adding to R&D woes
fiercebiotech
20d
GSK doubles down on Chimagen with $750M multiple myeloma wager
fiercebiotech
21d
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
21d
Psychedelic therapies ride wave of public favor into FDA hearing
biospace
24d
Yarrow brings in more cash; AbbVie drug succeeds in menstrual migraine trial
endpoints
24d
Frazier adds $1.1B+ to small and mid-sized biotech fund
biospace
25d
Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'
biospace
26d
Beyond China: Five other overseas destinations for biopharma dollars
biospace
27d
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
fiercebiotech
27d
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
fiercebiotech
29d
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
fiercebiotech
Sep 5, 26
AbbVie-allied ADARx aims for IPO with three drugs in the clinic
endpoints
Sep 4, 26
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
biopharma dive
Sep 4, 26
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
biopharma dive
Sep 4, 26
Biotech is back, with H1 progress smoothing glide path through end of year: Truist
biospace
Sep 4, 26
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
biospace
← prev
page 2 of 5
next →
